COVID-19: Melatonin as a potential adjuvant treatment

被引：10
|
作者：
Salles, Cristina [1 ]
机构：
[1] Bahianas Sch Med & Publ Hlth, Salvador, BA, Brazil
来源：
LIFE SCIENCES | 2020年 / 253卷
关键词：
D O I：
10.1016/j.lfs.2020.117716
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)
    Sehirli, Ahmet Ozer
    Sayiner, Serkan
    Serakinci, Nedime
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (10) : 8229 - 8233
  • [22] Montelukast as a potential treatment for COVID-19
    McCarthy, Matthew. W. W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (05) : 551 - 555
  • [23] Simnotrelvir as a potential treatment for COVID-19
    McCarthy, Matthew W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (03) : 233 - 237
  • [24] As a potential treatment of COVID-19: Montelukast
    Fidan, Cihan
    Aydogdu, Ayse
    MEDICAL HYPOTHESES, 2020, 142
  • [25] Curcumin as a Potential Treatment for COVID-19
    Rattis, Brune A. C.
    Ramos, Simone G.
    Celes, Mara R. N.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] Curcumin as a potential treatment for COVID-19
    Rocha, Francisco Airton Castro
    Assis, Marcos Renato
    PHYTOTHERAPY RESEARCH, 2020, 34 (09) : 2085 - 2087
  • [27] Ensitrelvir as a potential treatment for COVID-19
    McCarthy, Matthew W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (18) : 1995 - 1998
  • [28] Metformin as a potential treatment for COVID-19
    MCCarthy, Matthew W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1199 - 1203
  • [29] Infliximab as a potential treatment for COVID-19
    Velez, Matthew P.
    McCarthy, Matthew W.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (01) : 1 - 5
  • [30] Ivermectin as a potential treatment for COVID-19?
    Chosidow, Olivier
    Bernigaud, Charlotte
    Guillemot, Didier
    Giraudeau, Bruno
    Lespine, Anne
    Changeux, Jean-Pierre
    Bourhy, Herve
    Lecuit, Marc
    Amoura, Zahir
    PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (06):
12345